Lexaria Bioscience Corp. has announced the commencement of its 2026 research and development program, a strategic initiative aimed at broadening pharmaceutical, intellectual property, and business development opportunities through new and improved formulations. The company released details on three representative studies that will constitute primary areas of focus during at least the first three quarters of the calendar year, though these do not encompass the entire 2026 R&D Program.
CEO Richard Christopher emphasized the practical orientation of this year's research agenda, stating that the studies are specifically concentrated on increasing the likelihood of pharma industry partnerships and the creation of new intellectual property. Some aspects of the work remain intentionally obscure at this stage, as successful outcomes could lead to expanded new IP and patent development.
The human study, designated GLP-1-H26-7, is expected to be a 5-week parallel group study with three different arms. Primary goals include establishing safety and tolerability, as well as pharmacokinetic evaluation, comparing salcaprozate sodium-inclusive DehydraTECH-semaglutide tablet and capsule compositions to the commercially available Wegovy semaglutide tablets under fasted pre-dose conditions. This study will evaluate differences between DehydraTECH capsules traditionally optimized for intestinal absorption and DehydraTECH tablets experimentally optimized for primarily stomach absorption.
Study GLP-1-H26-7 will expand upon findings from Human Pilot Study #1 which delivered promising pharmacokinetic and safety results with an earlier iteration of SNAC-inclusive DehydraTECH-semaglutide capsules. The new study will be more robust, with approximately 30 subjects expected in each tablet comparison arm and 15 subjects in the capsule study arm, improving prospective statistical reliability of the data generated. Lexaria is working with third-party service providers with intent to begin recruitment as early as April, with ethics board submissions to follow, and a final study report expected in Q4 2026.
Two animal studies complement the human research. Animal Study GLP-1-A26-1 is expected to be a large, single-dose study with 8-11 different arms, testing various SNAC-inclusive DehydraTECH-semaglutide formulations and various DehydraTECH-cannabidiol formulations. A unique aspect involves taking brain samples since DehydraTECH has previously evidenced superior absorption of active ingredients into brain tissue, an area of intense interest given that GLP-1 drug performance increasingly appears to depend upon brain neurochemistry involvement.
Animal Study GLP-1-A26-2 will focus on delivery of DehydraTECH enhanced retatrutide and amycretin, both GLP-1 drugs Lexaria has never studied before. The inclusion of retatrutide marks the first time the company has worked with a triple agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors. Some study arms will compare pharmacokinetic performance of test articles placed endoscopically in the intestine versus being swallowed to target the stomach, comparing formulation functionality in distinct gastrointestinal dosing regions.
Both animal studies are anticipated to begin by Q2 2026 with final reports expected near the end of Q3 2026. Each study will be conducted by independent third-party service providers and individually announced with additional details once ready to proceed. Additional R&D work not yet disclosed may be completed during 2026.
The implications of this research program extend beyond Lexaria's immediate business interests. Successful outcomes could potentially advance oral delivery methods for GLP-1 medications, a drug class experiencing explosive growth for diabetes and weight management applications. Enhanced brain absorption capabilities could open new therapeutic avenues for neurological conditions. The pursuit of new intellectual property through these studies represents a strategic move to strengthen Lexaria's position in the competitive drug delivery technology landscape, potentially leading to valuable licensing agreements or partnerships with major pharmaceutical companies seeking improved oral formulations for their drug portfolios.
